Degarelix acetate
Sponsors
Novartis Pharma AG, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cancer Research Antwerp, Fudan University
Conditions
Cancer of ProstatePSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.Prostate CancerProstate Cancer Adenocarcinoma in Situ
Phase 1
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
CompletedNCT01696877
Start: 2013-01-18End: 2018-12-18Updated: 2019-03-28
SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mHSPC) and in men with heavily pre-treated PSMA positive metastatic castration resistant prostate cancer (mCRPC) with or without prior 177Lu-labelled PSMA-targeted radioligand therapy
Active, not recruitingCTIS2023-507672-52-00
Start: 2023-11-07Target: 32Updated: 2025-11-13
Phase 2
Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP
RecruitingNCT03899077
Start: 2019-04-05End: 2025-12-31Target: 202Updated: 2024-02-07
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
NCT05212857
Start: 2022-04-30End: 2024-09-30Target: 160Updated: 2022-03-16
An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan (AAA617) alone and lutetium [177Lu] vipivotide tetraxetan (AAA617) in combination with androgen receptor pathway inhibitors in patients with PSMA PET scan positive castration-resistant prostate cancer (PSMACare)
Active, not recruitingCTIS2022-503040-41-00
Start: 2024-02-09Target: 45Updated: 2025-12-16